Sarepta Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SRPT Nasdaq 2830 www.sarepta.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sarepta Therapeutics, Inc.

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - Jul 22nd, 2026 7:25 am
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results - Jul 22nd, 2026 6:30 am
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space - Jul 21st, 2026 2:04 pm
Sarepta Skids After A Rival Clears A Key Hurdle In The Duchenne Space - Jul 20th, 2026 2:28 pm
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - Jul 17th, 2026 12:52 pm
Following FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued? - Jul 13th, 2026 7:10 pm
The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies - Jul 13th, 2026 6:22 pm
What It Means To Hold Moderna Stock In A Crash - Jul 13th, 2026 7:12 am
2 Beaten-Down Stocks That Still Aren't Worth Buying - Jul 11th, 2026 2:50 pm
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up - Jul 10th, 2026 1:37 pm
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout - Jul 10th, 2026 10:04 am
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act? - Jul 10th, 2026 6:14 am
The Long Climb Back For Ionis Stock - Jul 10th, 2026 5:35 am
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next - Jul 9th, 2026 5:03 am
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 30th, 2026 2:25 pm
SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies - Jun 30th, 2026 10:54 am
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53® - Jun 30th, 2026 6:30 am
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says - Jun 18th, 2026 9:04 am
Is Sarepta (SRPT) Using New Equity Plans To Quietly Redefine Its Post‑Profitability Playbook? - Jun 8th, 2026 3:19 pm
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy - Jun 8th, 2026 10:00 am